bioMérieux - 2022 Financial Results

Marcy l’Etoile (France) – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 7 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial statements for the year ending December 31, 2022.

Strong sales growth in the fourth quarter

• Organic growth of 5.9%
• Very high demand for respiratory panels within the “tripledemic” (Flu/Covid/RSV) context
• Remarkable growth in non-respiratory panels and Industrial Applications 

Strong performance in 2022 with robust full-year sales and 18.5% contributive operating margin, above initial expectations

• Full-year sales at €3,589 million with a reported growth of +6.3% 
• Almost neutral organic growth of +0.2%, thanks to a strong growth of BIOFIRE^® non-respiratory panels, a solid growth of Microbiology and Industrial Applications, offsetting the slowdown in Immunoassays and stable sales for respiratory panels
• Contributive operating income at €664 million, representing an operating margin of 18.5%, lower than exceptionally high level of 2021, but significantly higher than pre-pandemic margin levels

Confirmed 2023 guidance

• In 2023, excluding respiratory panels, sales growth is expected to reach +8% to +10% at constant exchange rates and scope of consolidation, driven by a solid growth of BIOFIRE^® non-respiratory panels as well as Microbiology and Industrial applications. Assuming a slowdown for respiratory panels sales, total Group sales would be evolving within a +4% to +6% range on a like-for-like basis.
• Contributive operating income before non-recurring items should be in a range of €600 million to €630 million, at forecasted exchange rates, including a 40 M€ estimated unfavorable foreign exchange impact.

Alexandre Mérieux, Chairman and Chief Executive Officer, says: “In 2022, bioMérieux achieved a solid performance and adjusted upward its guidance during the year. The year has been marked by the acquisition of Specific Diagnostics which reinforces our product offering and our long-standing commitment to the fight against antimicrobial resistance. 2022 has been also an intense year in R&D and launch of several new platforms that will contribute to strengthen our market positions and sustain our growth.”